Similarly, the classification of IBD patients according to their basal circulating levels of nicotinamide phosphoribosyltransferase (NAMPT) discriminates with high sensitivity and specificity for the patients that will benefit from ADA treatment [35]. Here, NAMPT is linked to inflammatory bowel disease.